The work is reported by Li He and Jennifer Whistler of the Ernest Gallo Clinic and Research Center and the University of California, San Francisco.
The analgesic effects of morphine arise through the interaction of the drug with a specialized protein on the surface of cells, the mu opioid peptide receptor, or "MOP" receptor. MOP receptors are also activated by other opioid drugs and by endogenous opioids, such as endorphins. However, morphine is unique in that unlike other opioids, it does not cause the MOP receptor to be internalized into the cell's interior after activation. It is thought that the activated receptor's persistence at the cell surface leads to a compensatory overactivation of a particular signaling pathway in the cell--a signaling imbalance that is a hallmark of opiate tolerance and dependence. This suggests that the promotion of MOP-receptor internalization might prevent such cellular signaling imbalances, and indeed past work from Whistler indicated that mutant versions of the receptor that are more readily internalized were associated with reduced levels of morphine tolerance in mice.
In the new work, the researchers sought a more clinically practical approach to facilitating MOP-receptor internalization in the presence of morphine. Reasoning that because other opioid drugs promote internalization of MOP receptors, and that their presence in combination with morphine may prevent the p
Contact: Heidi Hardman